Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda

Table 3 Complete case analysis

Characteristic	Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
Gender
Female	1.00		1.00
Male	3.09(1.80–5.31)	< 0.001	2.58(1.42–4.69)	0.002*
Type of second-line drugs
lopinavir	1.00		1.00
Atazanavir	1.59(0.44–5.82)	0.483	3.4(0.79–14.34)	0.101
Other PI^µ	5.66(1.92–16.66)	0.002	3.92(1.15–13.38)	0.671
TB treatment
No	1.00		1.00
Yes	7.54(2.69–21.08)	< 0.001	5.65(1.76–18.09)	0.004*
Year of ART initiation
Before 2001	1.00		1.00
2001–2005	0.05(0.01–0.16)	< 0.001	0.06(0.02–0.22)	< 0.001*
2006–2010	0.05(0.02–0.20)	< 0.001	0.07(0.02–0.28)	< 0.001*
2011–2015	0.02(0.00–0.17)	< 0.001	0.03(0.00–0.26)	0.002*
Type of 1^st line drug
NNRTI based	1.00
NON-NNRTI^∞	1.81(0.92–3.55)	0.085	–	–
Other comorbidities
No	1.00
Yes	1.00(0.44–2.26)	1.000	–	–
Age at start of 2^nd line
	0.99(0.97–1.01)	0.300	–	–
CD4 at start of second line
	0.99(0.99–1.00)	0.079	–	–
Duration on 1^st line
	1.07(0.96–1.18)	0.210

^¶ Wide confidence interval due to small sample size ^*statistically significant at the 5% level, TB: tuberculosis, VL: Viral Load, IQR: Interquartile Range, ART: Antiretroviral Therapy, ∞Non-NRTI: triple nucleosides, µ “other PI”: saquinavir and nelfinavir

ISSN: 1742-6405